Related references
Note: Only part of the references are listed.A Time to Keep and a Time to Cast Away Categories of Tumor Response
Michael L. Maitland et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Integrating predictive biomarkers and classifiers into oncology clinical development programmes
Robert A. Beckman et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Changing End Points in Breast-Cancer Drug Approval - The Avastin Story
Ralph B. D'Agostino
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Improved Endpoints for Cancer Immunotherapy Trials
Axel Hoos et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR
Volker Heinemann et al.
CANCER TREATMENT REVIEWS (2009)
I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
A. D. Barker et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Parallel Paths to Predictive Biomarkers in Oncology: Uncoupling of Emergent Biomarker Development and Phase III Trial Execution
Robert Sikorski et al.
SCIENCE TRANSLATIONAL MEDICINE (2009)
Optimal and minimax three-stage designs for phase II oncology clinical trials
Kun Chen et al.
CONTEMPORARY CLINICAL TRIALS (2008)
Setting the bar in phase II trials: The use of historical data for determining go/no go decision for definitive phase III testing
Andrew J. Vickers et al.
CLINICAL CANCER RESEARCH (2007)
Some design issues in trials of microbicides for the prevention of HIV infection
TR Fleming et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
Share Paper
